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ABSTRACT 
Risperidone is a serotonin - dopamine antagonist which has got less propensity to cause tardive 
dyskinesia than conventional antipsychotics. There have been few reports of tardive dyskinesia induced 
by risperidone. This is a report of a case of risperidone induced tardive dyskinesia. A 56 year old 
female with a 6 months history of paranoid schizophrenia, developed bucco-oro-masticatory abnormal 
involuntary movements after receiving risperidone 8 mg/day for about 1 year. She had some of the 
risk factors for the development of tardive dyskinesia like age, sex, anti-chotinergic drugs and earlier 
emergence of neuroleptic-induced parkinsonism. Clinicians must be aware of the possibility of the 
patients developing tardive dyskinesia when they are given the supposedly safe neuroleptic risperidone. 
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Tardive dyskinesia (TD) is a well recognized 
adverse effect associated with the long-term use 
of neuroleptic therapy, characterized by 
involuntary, choreiform, athetoid or rhythmic 
movements of the tongue jaw and / or extremities. 
Because it can be disfiguring, persistent and even 
permanent, it has been a major limiting factor in 
the use of antipsychotic medications (Daniel et 
al, 2000). The overall prevalence of neuroleptic -
induced TD in individuals who have received long 
term neuroleptic treatment ranges from 20% - 30% 
(APA, 1994). The most significant and 
consistently documented risk factors for the 
development of TD is increasing age of the patient 
(Jeste & Wyatt, 1982;Kane & Smith, 1982). 
Women have been found to be at a greater risk 
for severe TD, especially the geriatric populations 
(Kennedy et al., 1971). It was hoped that the 
emerging generation of putative atypical 
antipsychotics such as, risperidone, olanzapine, 
sertindole, quetiapine and ziprasidone will have a 
reduced liability to produce TD. Herein, we report 
a case of TD induced by risperidone. 
CASE REPORT 
This patient, 56 year old female, was 
brought with 6 months duration of bizarre 
delusions of persecution, thought withdrawal and 
broadcast, somatic hallucination and second and 
third person auditory hallucinations, with no 
evidence of any substance abuse or organic 
pathology and no contributory past or family 
histories and the patient never received treatment 
with any neuroleptics prior to this. The patient was 
admitted and a diagnosis of paranoid 
schizophrenia was made (DCR-10) (WHO, 1993). 
She was started on risperidone, from 1 mg/day 
initially and at the time of discharge in 2 weeks, 
the dosage was increased to 8 mg/day. During 
the course of her stay in the hospital, she 
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developed neuroleptic- induced Parkinsonism and 
for which, 2 mg/day of Trihexypenidyl (THP) was 
added. In about 11 months of time, her delusions 
more or less disappeared,but occasional auditory 
hallucinations were still persisting. So, risperidone 
was reduced to 6 mg/day along with 2 mg/day of 
THP. After about 1 V4 years, there was no active 
psychopathology, so risperidone was further 
reduced to 4 mg/day with 1 mg/day of THP. During 
her next follow up, after a month, we noticed a 
typical choreiform and athetoid bucco-oro-
masticatory movements in her, characterized by 
pouting, puckering and smacking of lips and 
chewing movements of the lower jaw. There were 
no abnormal movements in the tongue, trunk or 
extremities. The patient was not aware of and did 
not present subjective complaints of the abnormal 
movements. Her son reported that these 
movements were transiently reduced by voluntary 
movements of the jaw and absent during sleep. 
So, risperidone was stopped and olanzapine 7.5 
mg/day was started. During the next visit, after a 
month, there was no change in the movements 
and the patient is continuing on olanzapine. 
DISCUSSION 
Risperidone is a benzisoxizole derivative, 
the second serotonin-dopamine antagonist, after 
clozapine, to be introduced in India. The incidence 
of TD in patient treated with risperidone for atleast 
1 year has been estimated at around 0.3% 
(Brecher, 1996; Ayd & Pies, 1997). 
In our patient, she had both the significant 
and consistently documented risk factors for the 
development of TD - increasing age (>55 years) 
and female sex. Several investigators suggested 
that, one risk factor for developing TD is earlier 
emergence of other extrapyramidal symptoms 
(Owens, 1994). This patient had neuroleptic -
induced Parkinsonism during admission. There 
is a hypothesis that anticholinergic medications 
also contribute to the development of TD (Kane, 
1995). Our patient was treated with THP after she 
developed neuroleptic - induced Parkinsonism. 
However, there is no clear evidence for this 
hypothesis. 
There have been isolated case reports of 
patients developing TD. when they were treated 
with a dosage of risperidone, 6 mg/day or higher. 
Unlike previous, this one clearly demonstrates the 
cause-and-effect relationship of risperidone and 
TD in a patient whose clinical course was well 
documented But a single case can only serve to 
stimulate interest in further study We want the 
clinicians to be aware of the possibility of patients 
developing TD when they are given the supposedly 
safe neuroleptic risperidone. 
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